Global Bulk Drug Market (Sales, Revenue, Price, Gross Profit and Competitors Analysis of Major Market) from 2015-2026
- Published Date: 2021-01-25
- Report ID: 44301
- Pages: 124
-
Format:
Summary
As the world continues to deal with COVID-19, economies are moving into recession, under multiple adverse factors, the GDP of European and American countries in the second quarter suffered a historical contraction. At an annualized rate, the US GDP fell by 32.9% month on month, while the overall GDP of the euro zone fell by 12.1%.
Moreover, the economic prospects of Europe and the United States in the third quarter under the epidemic situation are hardly optimistic. The resumption of work and production not only brought economic data back, but also triggered a rebound in the epidemic situation. At present, the United States is still the 'epicenter' of the global epidemic. The total number of confirmed cases has exceeded 4.8 million, and the epidemic situation in some European countries has also rebounded. Affected by this, more than 20 states in the United States have announced the suspension or withdrawal of part of the economic restart plan. Britain and Italy have also decided to extend the state of emergency. The rebound of the epidemic situation has posed considerable risks to the economic prospects of Europe and the United States.
In the second quarter of this year, US GDP shrank by 9.5% on a month on month basis, or 32.9% at an annual rate, the largest decline since the 1940s. Data show that the sharp decline in personal consumption is the main drag on the U.S. GDP growth in the second quarter.
Compared with the United States, Europe's economic contraction in the second quarter was smaller, but it was also the lowest on record, with Germany and France contracting more than 10%. According to the data released by the Federal Bureau of statistics, Germany's GDP fell by 10.1% in the second quarter after adjusting for prices, seasons and working days, the largest decline since the quarterly economic data were available in 1970.
Thanks to the effective control and policy support of the new epidemic, China's economy rebounded sharply in the second quarter. The growth rate of manufacturing industry, which accounted for about 28% of GDP, rebounded sharply to 4.4% from the negative value in the first quarter. Chinese original equipment manufacturers (OEMs) and suppliers are ramping up production. And there are increased investments in digital footprints in manufacturing. OEMs in other parts of the world are offering incentives to drive sales. Prudent Markets published a report for global Bulk Drug market in this environment.
In terms of revenue, this research report indicated that the global Bulk Drug market was valued at USD XXX million in 2019, and it is expected to reach a value of USD XXX million by 2026, at a CAGR of XX % over the forecast period 2021-2026. Correspondingly, the forecast analysis of Bulk Drug industry comprises of China, USA, Japan, India, Korea and South America, with the production and revenue data in each of the sub-segments.
The Teva aims at producing XX Bulk Drug in 2020, with XX % production to take place in global market, Novartis accounts for a volume share of XX %.
Regional Segmentation (Value; Revenue, USD Million, 2015 - 2026) of Bulk Drug Market by Prudent Markets Include
China
EU
USA
Japan
India
Southeast Asia
South America
Competitive Analysis; Who are the Major Players in Bulk Drug Market
Teva
Novartis
Pfizer
Johnson and Johnson
Mylan
North China Pharmaceutical Group
Dr. Reddys Laboratories
Roche
Aurobindo pharma
Sun Pharmaceutical Industries
Boehringer Ingelheim GmbH
Bayer
BASF
DSM
Zhejiang Medicine
Biocon
Johnson Matthey
Hisun Pharmacy
Cambrex
Shandong Xinhua Pharmaceutical
Lonza group
Huahai Pharmaceutical
Haerbin Pharmaceutical Group
...
Major Type of Bulk Drug Covered in Prudent Markets report:
Vitamin
Antibiotic
Iohexol
Hormone
Amino Acid
Application Segments Covered in Prudent Markets Market
Orthopedics Disease
Others
Application 3
For any other requirements, please feel free to contact us and we will provide you customized report.
Table of Contents
Global Bulk Drug Market Analysis 2020, With Top Companies, Production, Revenue, Consumption, Price and Growth Rate
1 Market Scope
1.1 Product Details and Introduction
1.1.1 Vitamin -Product Introduction and Major Manufacturers
1.1.2 Antibiotic -Product Introduction and Major Manufacturers
1.1.3 Iohexol -Product Introduction and Major Manufacturers
1.1.4 Hormone -Product Introduction and Major Manufacturers
1.1.5 Amino Acid -Product Introduction and Major Manufacturers
1.2 Market Snapshot
1.2.1 Major Companies Overview
1.2.2 Market Concentration
1.2.3 Six-Year Compound Annual Growth Rate (CAGR)
2 Global Bulk Drug Market Assessment, by Segmentation
2.1 Type Breakdown Estimates & Forecast, Sales Volume (2015-2026)
2.2 Type Breakdown Estimates & Forecast, Sales Value (2015-2026)
2.3 Application Breakdown Estimates & Forecast, by Application (2015-2026)
3 Regional Market Analysis
3.1 China Bulk Drug Market
3.1.1 Top Companies leading Bulk Drug Development in China (2015-2020)
3.1.2 Sales Value of Major Company in China Market (2015-2020)
3.1.3 China Bulk Drug Price (USD/Unit), by Type (2019-2020)
3.1.4 Sales in China Market, by Type (2015-2026)
3.2 EU Bulk Drug Market
3.2.1 Top Companies leading Bulk Drug Development in EU (2015-2020)
3.2.2 Sales Value of Major Company in EU Market (2015-2020)
3.2.3 EU Bulk Drug Price (USD/Unit), by Type (2019-2020)
3.2.4 Sales in EU Market, by Type (2015-2026)
3.3 USA Bulk Drug Market
3.3.1 Top Companies leading Bulk Drug Development in USA (2015-2020)
3.3.2 Sales Value of Major Company in USA Market (2015-2020)
3.3.3 USA Bulk Drug Price (USD/Unit), by Type (2019-2020)
3.3.4 Sales in USA Market, by Type (2015-2026)
3.4 Japan Bulk Drug Market
3.4.1 Top Companies leading Bulk Drug Development in Japan (2015-2020)
3.4.2 Sales Value of Major Company in Japan Market (2015-2020)
3.4.3 Japan Bulk Drug Price (USD/Unit), by Type (2019-2020)
3.4.4 Sales in Japan Market, by Type (2015-2026)
3.5 India Bulk Drug Market
3.5.1 Top Companies leading Bulk Drug Development in India (2015-2020)
3.5.2 Sales Value of Major Company in India Market (2015-2020)
3.5.3 India Bulk Drug Price (USD/Unit), by Type (2019-2020)
3.5.4 Sales in India Market, by Type (2015-2026)
3.6 Southeast Asia Bulk Drug Market
3.6.1 Top Companies leading Bulk Drug Development in Southeast Asia (2015-2020)
3.6.2 Sales Value of Major Company in Southeast Asia Market (2015-2020)
3.6.3 Southeast Asia Bulk Drug Price (USD/Unit), by Type (2019-2020)
3.6.4 Sales in Southeast Asia Market, by Type (2015-2026)
3.7 South America Bulk Drug Market
3.7.1 Top Companies leading Bulk Drug Development in South America (2015-2020)
3.7.2 Sales Value of Major Company in South America Market (2015-2020)
3.7.3 South America Bulk Drug Price (USD/Unit), by Type (2019-2020)
3.7.4 Sales in South America Market, by Type (2015-2026)
4 Value Chain (Impact of COVID-19)
4.1 Bulk Drug Value Chain Analysis
4.1.1 Upstream
4.1.2 Downstream
4.2 COVID-19 Impact on Bulk Drug Industry
4.2.1 Industrial Policy Issued Under the Epidemic Situation
4.3 Cost-Under the Epidemic Situation
4.3.1 Cost of Raw Material
4.4 Channel Analysis
4.4.1 Distribution Channel-Under the Epidemic Situation
4.4.2 Distributors
5 Regional Market Forecast (2021-2026)
5.1 Global Bulk Drug Sales and Growth Rate (2021-2026)
5.2 Global Bulk Drug Sales Value and Growth Rate (2021-2026)
6 Bulk Drug Competitive Analysis
6.1 Teva
6.1.1 Teva Company Profiles
6.1.2 Teva Product Introduction
6.1.3 Teva Bulk Drug Production, Revenue (2015-2020)
6.1.4 SWOT Analysis
6.2 Novartis
6.2.1 Novartis Company Profiles
6.2.2 Novartis Product Introduction
6.2.3 Novartis Bulk Drug Production, Revenue (2015-2020)
6.2.4 SWOT Analysis
6.3 Pfizer
6.3.1 Pfizer Company Profiles
6.3.2 Pfizer Product Introduction
6.3.3 Pfizer Bulk Drug Production, Revenue (2015-2020)
6.3.4 SWOT Analysis
6.4 Johnson and Johnson
6.4.1 Johnson and Johnson Company Profiles
6.4.2 Johnson and Johnson Product Introduction
6.4.3 Johnson and Johnson Bulk Drug Production, Revenue (2015-2020)
6.4.4 SWOT Analysis
6.5 Mylan
6.5.1 Mylan Company Profiles
6.5.2 Mylan Product Introduction
6.5.3 Mylan Bulk Drug Production, Revenue (2015-2020)
6.5.4 SWOT Analysis
6.6 North China Pharmaceutical Group
6.6.1 North China Pharmaceutical Group Company Profiles
6.6.2 North China Pharmaceutical Group Product Introduction
6.6.3 North China Pharmaceutical Group Bulk Drug Production, Revenue (2015-2020)
6.6.4 SWOT Analysis
6.7 Dr. Reddys Laboratories
6.7.1 Dr. Reddys Laboratories Company Profiles
6.7.2 Dr. Reddys Laboratories Product Introduction
6.7.3 Dr. Reddys Laboratories Bulk Drug Production, Revenue (2015-2020)
6.7.4 SWOT Analysis
6.8 Roche
6.8.1 Roche Company Profiles
6.8.2 Roche Product Introduction
6.8.3 Roche Bulk Drug Production, Revenue (2015-2020)
6.8.4 SWOT Analysis
6.9 Aurobindo pharma
6.9.1 Aurobindo pharma Company Profiles
6.9.2 Aurobindo pharma Product Introduction
6.9.3 Aurobindo pharma Bulk Drug Production, Revenue (2015-2020)
6.9.4 SWOT Analysis
6.10 Sun Pharmaceutical Industries
6.10.1 Sun Pharmaceutical Industries Company Profiles
6.10.2 Sun Pharmaceutical Industries Product Introduction
6.10.3 Sun Pharmaceutical Industries Bulk Drug Production, Revenue (2015-2020)
6.10.4 SWOT Analysis
6.11 Boehringer Ingelheim GmbH
6.12 Bayer
6.13 BASF
6.14 DSM
6.15 Zhejiang Medicine
6.16 Biocon
6.17 Johnson Matthey
6.18 Hisun Pharmacy
6.19 Cambrex
6.20 Shandong Xinhua Pharmaceutical
6.21 Lonza group
6.22 Huahai Pharmaceutical
6.23 Haerbin Pharmaceutical Group
7 Conclusion
Call Us
( India toll free )
+91 835 605 0278
( US toll free )
+1 800 601 6071
Drop us an email at
sales@prudentmarkets.com
Get your pre and post sales queries resolved by our Subject matter experts.
We will assist you to customize the report to fit your research needs.
Our prime focus is to provide qualitative and accurate data.
Feel free to order a sample report before purchase.
Your personal and confidential information is safe and secured.
